Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: A randomized, double-blind, placebo-controlled trial
Under a Creative Commons license
open access
Keywords
Schizophrenia
Cariprazine
Long-term treatment
Relapse prevention
Randomized controlled trial
Oral antipsychotics
Cited by (0)
- 1
Dayong Li is currently an employee of AstraZeneca, Gaithersburg, MD, USA.
© 2016 The Authors. Published by Elsevier B.V.